Abstracts Archive - Page 117 of 2607 - ACR Meeting Abstracts

Abstract Number: 1470 • ACR Convergence 2025
Why Do Some Lupus Patients Skip Their Mycophenolate Mofetil? A Multi-Factorial Assessment of Patient Compliance
Nidaa Bukhari¹, Ali Rizvi¹, Jian sun¹, Zerai Manna², Paul Schaughency³, Suraj Rajasimhan⁴ and Sarfaraz Hasni¹, ¹National Institutes of Health, BETHESDA, MD, ²NIH, Bethesda, MD, ³NIAID, NIH, Bethesda, MD, ⁴National Institutes of Health, Columbia, MD
Background/Purpose: Nonadherence to medication is a significant confounder in assessing treatment efficacy for systemic lupus erythematosus (SLE), with rates reported up to 75% depending on…
Abstract Number: 1471 • ACR Convergence 2025
Prevalence and Clinical Outcomes of Hemophagocytic Lymphohistiocytosis in Systemic Lupus Erythematosus: A Multi-Institutional Cohort Study
Amir Daneshvar¹, Julia Wajsberg¹, Chelsea Guan¹, Keri Ann Pfeil¹, Elleson Harper¹, Lindsay Frumker², Meghan Gump¹ and Omer Pamuk³, ¹University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH, ²University hospitals Cleveland medical center, Highland Heights, OH, ³University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with multisystem involvement. A rare but life-threatening hyper-inflammatory hematological complication of SLE is hemophagocytic lymphohistiocytosis…
Abstract Number: 1408 • ACR Convergence 2025
When Damage and Disability Diverge: Unraveling Sex-Based Drivers of Axial Spondyloarthritis Burden
Claudia Marques¹, Gustavo Resende², Carla Saad³, Adriana Marinho⁴, Andressa Soares⁵, Beatriz Paiva⁶, Cleandro Pires⁷, Débora Rodrigues⁸, Glaucio Castro⁹, Guilherme Bulbol¹⁰, Jamile Carneiro¹¹, Manuella Ochtrop¹², José Mauro Fernandes¹³, Maria Bernadete Gavi¹⁴, Maria Eduarda Veiga³, Michel Yazbek¹⁵, Nara Cavalcanti¹⁶, Natalia Machado¹⁷, Olivio Malheiro¹⁸, Rafael Bassara Macedo¹⁹, Rejane Vieira²⁰, Ricardo Lage¹⁸, Rita Menin²¹, Rywka Golebiovski²², Sandra Ribeiro¹⁰, Thauana Oliveira²², Valquiria Diniz¹⁴, Percival Sampaio-Barros²³ and Marcelo Pinheiro²⁴, ¹Hospital das Clinicas - Universidade Federal de Pernambuco - UFPE, Recife, Pernambuco, Brazil, ²Hospital das Clinicas UFMG, Belo Horizonte, Brazil, ³Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, ⁴Fundação Hospital do Acre - AC, Rio Branco, Brazil, ⁵Hospital Universitário da Universidade Federal de Santa Catarina (UFSC) - SC, Florianópolis, Brazil, ⁶Faculdade de Medicina da Universidade Federal do Amazonas (UFAM) - AM, Manaus, Brazil, ⁷UNB, Brasilia, Distrito Federal, Brazil, ⁸Fundação Hospital do Acre - AC, Rio Branco, Acre, Brazil, ⁹Hospital Governador Celso Ramos (HCR) - SC, Florianópolis, Santa Catarina, Brazil, ¹⁰Faculdade de Medicina da Universidade Federal do Amazonas (UFAM) - AM, Manaus, Amazonas, Brazil, ¹¹Hospital de Base do Distrito Federal (HBDF) - DF, Brasilia, Distrito Federal, Brazil, ¹²Hospital Universitário Pedro Ernesto / UERJ - RJ, Rio de Janeiro, Rio de Janeiro, Brazil, ¹³Universidade Federal do Maranhão (UFMA) - MA, São Luiz, Maranhao, Brazil, ¹⁴Universidade Federal do Espírito Santo (UFES) - ES, Vitória, Espirito Santo, Brazil, ¹⁵Universidade Estadual de Campinas (UNICAMP) - SP, Campinhas, Sao Paulo, Brazil, ¹⁶Hospital das Clínicas da Universidade Federal de Pernambuco (UFPE) - PE, Recife, Pernambuco, Brazil, ¹⁷Universidade Fedral do Paraná (UFPR) - PR, Curitiba, Parana, Brazil, ¹⁸Hospital das Clínicas da Universidade Federal de Minas Gerais (UFMG) - MG, Belo Horizonte, Minas Gerais, Brazil, ¹⁹Rheumatology Division, Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo (USP), Sao Paulo, Sao Paulo, Brazil, ²⁰Universidade Estadual do Ceará (UECE) - CE, Fortaleza, Ceara, Brazil, ²¹Faculdade de Medicina de São José do Rio Preto (FAMERP) - SP, São José do Rio Preto, Sao Paulo, Brazil, ²²Escola Paulista de Medicina (EPM) - Universidade Federal de São Paulo (UNIFESP) - SP, São Paulo, Sao Paulo, Brazil, ²³Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, Brazil, ²⁴UNIFESP/ EPM, São Paulo, São Paulo, Brazil
Background/Purpose: Sex differences in axial spondyloarthritis (axSpA) are well recognized, but their clinical consequences remain understudied in real-world settings. This study aimed to assess sex-based…
Abstract Number: 1277 • ACR Convergence 2025
Combination Therapy with Rituximab and Cyclophosphamide for Treating Pediatric Patients with Severe Manifestations of Rheumatic Disease
Eileen Rife¹, Daniel Reiff², John Bridges³, Emily Smitherman¹, randy Cron¹, Matthew Stoll¹, Melissa Mannion¹, Peter Weiser⁴ and Livie Timmerman⁵, ¹University of Alabama at Birmingham, birmingham, AL, ²Boys Town Hospital, Omaha, ³University of Alabama at Birmingham/Children's of Alabama, Birmingham, AL, ⁴University of Alabama at Birmingham, Birmingham, ⁵University of Alabama at Birmingham, Gardendale, AL
Background/Purpose: Current practice guidelines recommend either rituximab (RTX) or cyclophosphamide (CYC) for treatment of organ-threatening manifestations of systemic vasculitis or connective tissue disease (e.g., diffuse…
Abstract Number: 1390 • ACR Convergence 2025
Cystic Lung Disease and Autoantibodies in Lymphocytic Interstitial Pneumonia: Exploring the Impact of Sjögren’s Syndrome
KARLA CHACON¹, ALBERTO ALEJANDRO MARQUEZ-SANCHEZ¹, Jorge Rojas-Serrano² and MAYRA MEJÍA¹, ¹Instituto Nacional de Enfermedades Respiratorias, CIUDAD DE MEXICO, Distrito Federal, Mexico, ²Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico
Background/Purpose: Lymphocytic interstitial pneumonia (LIP) is a rare interstitial lung disease, most commonly associated with Sjögren’s syndrome, but it may also occur in the context…
Abstract Number: 1479 • ACR Convergence 2025
Validation of Attention, Memory, and Frontal-Executive Abilities Screening Test (AMFAST) in Systemic Lupus Erythematosus (SLE), a prospective single-center study in The Bronx
Chen Chao¹, Garrett Thomas², Catherine O’Brien², Davina Chen³, Sundus Mian⁴, Tamar Rubinstein⁵, Noa Schwartz⁴ and Bryan Freilich², ¹Rheumatology Division, Department of Medicine, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, NY, ²Department of Psychiatry, Montefiore Medical Center, Bronx, NY, ³Division of Rheumatology, Department of Medicine, Montefiore Medical Center, New Rochelle, NY, ⁴Division of Rheumatology, Department of Medicine, Montefiore Medical Center, New York, NY, ⁵Albert Einstein College of Medicine, White Plains, NY
Background/Purpose: Up to 80% of Systemic Lupus Erythematosus (SLE) patients experience cognitive dysfunction (CD), which is a top distressing symptom affecting their quality of life.(1)…
Abstract Number: 1494 • ACR Convergence 2025
Comparing Childhood-Onset Versus Adult-Onset Systemic Lupus Erythematosus Young Adults’ Lived Employment Experiences
NILOFAR JAHAGHI¹, Michael Golding², Fareha Nishat³, Kaitlyn Merrill², Diane Lacaille⁴, Umut Oguzoglu², Roberta Woodgate², Jennifer Stinson⁵, Christine Peschken⁶, Zahi Touma⁷, Jennifer Protudjer² and Lily Lim⁶, ¹Karolinska Institutet, Stockholm, Sweden, ²University of Manitoba, Winnipeg, Canada, ³University of Toronto, Toronto, Canada, ⁴Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ⁵The Hospital for Sick Children, Toronto, ON, Canada, ⁶University of Manitoba, Winnipeg, MB, Canada, ⁷University of Toronto, Toronto, ON, Canada
Background/Purpose: Young adulthood (18-30 years) is a life stage with many transitions. Young adults with Systemic Lupus Erythematosus must navigate this period while living with…
Abstract Number: 1460 • ACR Convergence 2025
Effect of Guselkumab and IL-17 Inhibitors on Work Productivity and Activity Impairment in Psoriatic Arthritis: 6-Month Results of the PsABIOnd Observational Study
Stefan Siebert¹, Mohamed Sharaf², Frank Behrens³, Proton Rahman⁴, mitsumasa kishimoto⁵, Enrique R. Soriano⁶, Emmanouil Rampakakis⁷, László Köleséri⁸, Karissa Lozenski⁹, Ruben Queiro¹⁰, Ennio Lubrano¹¹ and Laure Gossec¹², ¹University of Glasgow, Glasgow, United Kingdom, ²Janssen - Johnson & Johnson, Dubai, United Arab Emirates, ³Goethe-University & Fraunhofer ITMP, Frankfurt, Germany, ⁴Division of Rheumatology, Craig L. Dobbin Genetics Research Centre, Discipline of Medicine, Memorial University of Newfoundland, St. John's, Canada, ⁵Kyorin University School of Medicine, Tokyo, Japan, ⁶Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires and University Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁷JSS Medical Research, Montréal, QC, Canada, ⁸IQVIA, Budapest, Hungary, ⁹Johnson & Johnson, Horsham, PA, ¹⁰Hospital Universitario Central de Asturias, Oviedo. Asturias, Spain, ¹¹Department of Medicine, Università deglia Studi del Molise, CAMPOBASSO, Italy, ¹²Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France
Background/Purpose: Work impairment is a key issue in PsA. Biologic treatments can improve work status in patients (pts) with PsA; however, there is lack of…
Abstract Number: 1418 • ACR Convergence 2025
Impact of Type 2 Diabetes Mellitus on Cardiovascular Outcomes in Patients with Ankylosing Spondylitis on NSAID Therapy
Godbless Ajenaghughrure¹, Sila Mateo Faxas², Gurjot Singh³, Nirys Mateo Faxas⁴, Kim Nguyen³, Nicole Tejeda⁵ and Kimberly Ramirez Bonetti⁶, ¹Trihealth Good Samaritan Hospital, Cincinnati, OH, ²Good Samaritan Hospital, Cincinnati, OH, ³Trihealth Good Samaritan Hospital, Cincinnati, ⁴Independent Author, Santo Domingo, Dominican Republic, ⁵Independent Author, Cincinnati, ⁶Independent Author, cincinnati, OH
Background/Purpose: Patients with ankylosing spondylitis (AS) have increased cardiovascular risk, potentially exacerbated by NSAID therapy. However, the additional impact of Type 2 diabetes mellitus (T2DM)…
Abstract Number: 1279 • ACR Convergence 2025
Whole Blood Gene Expression Defined Subgroups of Treatment Naïve Children and Adolescents with Childhood-onset Systemic Lupus Erythematosus.
Reagan Reid¹, Huayun Hou², Isha Datar², Daniela Dominguez³, Andrea Knight⁴, Deborah Levy⁵, Lawrence Ng⁶, Zhaoyu Ding², Michael Wilson², Lauren Erdman⁷, Eleanor Pullenayegum² and Linda Hiraki⁵, ¹The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ²SickKids Research Institute, Toronto, ON, Canada, ³The Hospital for Sick Children, Toronto, Canada, ⁴Hospital for Sick Children, Toronto, ON, Canada, ⁵The Hospital for Sick Children, Toronto, ON, Canada, ⁶The Hospital for Sick Children, Toronto, Canada, Toronto, ON, Canada, ⁷University of Cincinnati, Cincinnati, OH
Background/Purpose: Childhood-onset systemic lupus erythematosus (cSLE) is a clinically and genetically heterogeneous disease. We aimed to define subgroups of new diagnosis patients based on treatment…
Abstract Number: 1393 • ACR Convergence 2025
Prevalence of Sjögren’s Disease in the United States – A Retrospective Cohort Study Among a Commercially Insured Population (2019-2023)
Minoti Ganguli, Annie Kilby, Ahva Shahabi and Tsu-Chieh Jay Lin, Amgen Inc., Thousand Oaks, CA
Background/Purpose: Sjögren’s disease (SjD) is a systemic autoimmune condition characterized by diverse clinical manifestations, which often complicates diagnosis and disease management1. Previous epidemiological estimates of…
Abstract Number: 1038 • ACR Convergence 2025
Real-World Immunosuppressant Treatment Patterns in Lupus Nephritis: A Retrospective Claims Database Analysis in the United States
Anisha Patel¹, Alexandra Miller¹, Lisa Lindsay¹, Danny Sheinson¹, Zhiyu Xia¹, William Pendergraft¹ and Maria Dall'Era², ¹Genentech, Inc., South San Francisco, CA, ²Division of Rheumatology, University of California, San Francisco, CA
Background/Purpose: LN is a severe manifestation of SLE requiring intensive management. We aimed to characterize real-world treatment patterns in newly diagnosed patients with LN within…
Abstract Number: 1466 • ACR Convergence 2025
Impact of Bimekizumab on Spinal MRI Inflammation and Structural Lesions in Patients with Radiographic Axial Spondyloarthritis: 2-Year CANDEN Scoring Results from a Phase 3 Study and Its Open-Label Extension
Walter P. Maksymowych¹, Robert G. W. Lambert², Victoria Navarro-Compan³, Xenofon Baraliakos⁴, Jason Coarse⁵, Natasha de Peyrecave⁶ and Mikkel Ostergaard⁷, ¹Department of Medicine, University of Alberta, ⁵⁶⁸ Heritage Building, Edmonton, AB, Canada, ²University of Alberta, Department of Radiology & Diagnostic Imaging, Edmonton, AB, Canada, ³Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ⁴Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁵UCB, Morrisville, NC, ⁶UCB, Brussels, Belgium, ⁷Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, and Copenhagen Center for Arthritis Research, Center for Rheumatology, Rigshospitalet, Glostrup, Denmark
Background/Purpose: Spinal inflammation and structural progression are key features of radiographic axial spondyloarthritis (r-axSpA).1 Canada-Denmark (CANDEN) scoring enables anatomical-based assessments of MRI inflammatory and structural…
Abstract Number: 1498 • ACR Convergence 2025
Both Race and Socioeconomic Status Affect Mortality in SLE
Gursimran Kaur¹, Daniel Goldman², Andrea Fava³, Laurence Magder⁴ and Michelle Petri², ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Timonium, MD, ³Johns Hopkins University, Baltimore, MD, ⁴University of Maryland, Baltimore, Baltimore, MD
Background/Purpose: A recent meta-analysis found an overall 2.87-fold increase in all-cause mortality in systemic lupus erythematosus (SLE) with cause-specific increases in renal disease, infections, cardiovascular…
Abstract Number: 1041 • ACR Convergence 2025
Associated Factors And Direct Cost Analysis Of Dose Reduction And Discontinuation Of Biological Therapies In Rheumatoid Arthritis And Spondyloarthritis: Findings From A Colombian Cohort Within The Framework Of An Integrated Management Model
Edwin Jauregui¹, Deisy Restrepo², Belcy Garzon², Alexis Atuesta², Nestor Correa², Jessica Barrera² and Andrea Rubio², ¹Riesgo de fractura S.A, Bogotá, Colombia, ²Riesgo de fractura S.A, Bogotá, Colombia
Background/Purpose: Dose reduction of biologic therapy (BT) in patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA) has been increasingly implemented in recent years, in accordance…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].